Brazil
1990-2000
Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16,1997, 1997-05-16
2005
U.S. DoS Cable: U.S. PHARMA FIRMS THREATENED WITH LICENSING (Brazil), June 3, 2005.
U.S. DoS Cable: BRAZIL GIVES ABBOTT TEN DAYS BEFORE BREAKING PATENT, June 28, 2005
U.S. DoS Cable: Brazil’s National Health Council Recommends Compulsory Licensing – August 12, 2005
U.S. DoS Cable: BRAZILIAN MOH SLOWS PACE ON COMPULSORY LICENSING – September 5, 2005
U.S. DoS Cable: ABBOTT AND GOB REACH DEAL TO AVOID COMPULSORY LICENSE, October 13, 2005
2007
2007: Brazil’s latest compulsory licensing announcement, 2007-04-26
KEI Statement on Brazil Compulsory License on efavirenz, May 4, 2007
U.S. State Department Cables on Brazil Patent Policy, 2007-10-03
2010
Brazil’s proposal at WIPO on patent limitations and exceptions (SCP/14/7), 2010-01-25
U.S. Department of State cables regarding Brazil and pharmaceutical patents and prices – 1986-1987, 2010-08-12
Paragraph 6 system: Brazilian intervention at the WTO TRIPS Council, 2010-11-01
2014
2014, BIO discussion of Brazil, 2014-02-13
2016
9 November 2016 – WTO TRIPS Council – Brazil’s intervention on the Report of the UN High-Level Panel on Access to Medicines, 2016-11-10
2017
1 March 2017 – WTO TRIPS Council – Brazil’s intervention on the Report of the UN High-Level Panel on Access to Medicines, 2017-03-03
WTO TRIPS Council: Brazil, China, Fiji, India, and South Africa table agenda item on IP and the Public Interest, 2017-06-06
June 2017 – WTO TRIPS Council – Statement of Brazil on IP and the Public Interest – Compulsory Licensing, 2017-06-14
WTO TRIPS Council (October 2017): Brazil documents the compulsory licensing of raltegravir in Germany, 2017-10-21
SCP27: KEI statement on pressures faced by Brazil and Colombia in using TRIPS flexibilities, 2017-12-13
Chile
2006
CPTech Response to 2006 PhRMA “Special 301” Submission for Chile, 2006-03-07
2017
Chilean Cámara de Diputados votes overwhelmingly to advance compulsory licensing of drug patents., 2017-01-25
Patients, Members of Congress Ask Chilean Government to Issue Compulsory Licenses on Prostate Cancer and HCV Drug Patents, 2017-03-21
Background FAQ on Chile compulsory licensing request for HCV and prostate cancer treatments, 2017-12-06
NGOs and patient groups call upon Chilean President, Minister of Health to issue a compulsory license for cancer and Hepatitis drugs, 2017-12-06
2018
Chilean Cámara de Diputados Votes Overwhelmingly To Proceed With Compulsory Licenses for HCV Drugs, 2018-01-03
Colombia
2008
2008: Colombian Submission to the WHO IGWG negotiation favors drug company positions on IP, 2008-03-07
2015
2015: Switzerland pressures Colombia to deny compulsory license on imatinib, 2015-08-17
2015: James Love and Andrew S. Goldman. Colombia Asked To Declare Excessive Price For Cancer Drug Contrary To Public Interest, Grounds For Compulsory License. Inside Views, IP-Watch.Org. December 3, 2015.
2016
2016: Colombia takes an important step in defining the public interest in compulsory licensing case, 2016-03-04
Colombia Technical Committee Recommends Declaration that a Compulsory License on Imatinib (Gleevec) Would Be in Public Interest, 2016-03-04
April 27, 2016 Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory license, 2016-05-11
Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for Napster, 2016-05-11
April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents, 2016-05-12
News reports on Senator Hatch pressure over Colombia compulsory license on Novartis drug, 2016-05-16
122 experts defend Colombia’s right to issue compulsory license on imatinib in face of U.S. pressure, 2016-05-18
Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License, 2016-05-19
Background FAQ on Glivec (imatinib) compulsory license in Colombia, 2016-05-19
Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib, 2016-05-25
WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies, 2016-05-25
15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia, 2016-05-26
Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug, 2016-05-27
WHO to Colombia Minister of Health: Unaffordable drug prices are a legitimate reason for issuing a compulsory license, 2016-05-28
28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug, 2016-05-28
Colombia Ministry of Health Announces that Negotiations With Novartis Have Failed; Declaration of Public Interest Imminent, 2016-06-09
US Chamber of Commerce defends Swiss drug company charging excessive prices in Colombia, 2016-06-10
Colombia Issues Public Interest Declaration To Lower Price of Glivec, 2016-06-15
Colombia finalizes 44% price reduction of leukemia drug Glivec, 2016-12-21
2017
FOIA documents. In 2015 Novartis asked U.S. Dept of Commerce to Pressure Colombia Against Compulsory License on Glivec, 2017-06-08
SCP27: KEI statement on pressures faced by Brazil and Colombia in using TRIPS flexibilities, 2017-12-13
2018
PhRMA letter on Colombia Resolution 5246, 2018-01-16
Ecuador
2012
Ecuador issues a compulsory license on abacavir/lamivudine on 12 November 2012, 2012-11-15
2015
KEI Special 301 supplemental comments: Compulsory Licensing not restricted to “Emergencies” or “Measure of Last Resort”, 2015-03-01